Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood (2023) 142 (Supplement 1): 105.

https://doi.org/10.1182/blood-2023-180952

Published: 2023

Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2023-191047

Published: 2023

Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett

Blood (2020) 135 (25): 2224–2234.

https://doi.org/10.1182/blood.2019003277

Published: 2020

Includes: Supplemental data

Journal Articles

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

David J. Straus, Sin-Ho Jung, Brandelyn Pitcher, Lale Kostakoglu, John C. Grecula, Eric D. Hsi, Heiko Schöder, Leslie L. Popplewell, Julie E. Chang, Craig H. Moskowitz, Nina Wagner-Johnston, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett

Blood (2018) 132 (10): 1013–1021.

https://doi.org/10.1182/blood-2018-01-827246

Published: 2018

Includes: Supplemental data

Journal Articles

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Ramiro Garzon, Michael Savona, Rachid Baz, Michael Andreeff, Nashat Gabrail, Martin Gutierrez, Lynn Savoie, Paul Morten Mau-Sorensen, Nina Wagner-Johnston, Karen Yee, Thaddeus J. Unger, Jean-Richard Saint-Martin, Robert Carlson, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Sharon Shacham, Michael Kauffman, Richard Stone

Blood (2017) 129 (24): 3165–3174.

https://doi.org/10.1182/blood-2016-11-750158

Published: 2017

Includes: Supplemental data

Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Blood (2016) 128 (22): 104.

https://doi.org/10.1182/blood.V128.22.104.104

Published: 2016

Journal Articles

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Blood (2016) 128 (22): 469.

https://doi.org/10.1182/blood.V128.22.469.469

Published: 2016

Journal Articles

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Laura K Schoch, MS, CRNP, Ivan Borrello, MD, Ephraim J. Fuchs, MD, Javier Bolanos-Meade, MD, Jeffrey Sean Huo, MD PhD, Ivana Gojo, MD, Nina Wagner-Johnston, MD, Gabrielle T Prince, MD, Shannon R. McCurdy, MD, B. Douglas Smith, MD, Amy E. DeZern, MD MHS, Margaret M. Showel, MD, David Loeb, MD PhD, Aziza T. Shad, MD, Richard J Jones, MD, Richard F. Ambinder, MD PhD, Douglas Gladstone, MD

Blood (2016) 128 (22): 4571.

https://doi.org/10.1182/blood.V128.22.4571.4571

Published: 2016

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Paul A Hamlin, Jr., MD, Ian Flinn, MD, Nina wagner-Johnston, MD, Jan A Burger, MD PhD, Glenn Michelson, MD, Anjali Pandey, PhD, Matt Birrell, Greg P. Coffey, PhD, Janet M Leeds, PhD, John T. Curnutte, MDPhD, Manish R. Patel, MD

Blood (2015) 126 (23): 3929.

https://doi.org/10.1182/blood.V126.23.3929.3929

Published: 2015

Journal Articles

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Ariela Noy, Jeannette Y. Lee, Ethel Cesarman, Richard Ambinder, Robert Baiocchi, Erin Reid, Lee Ratner, Nina Wagner-Johnston, Lawrence Kaplan

Blood (2015) 126 (2): 160–166.

https://doi.org/10.1182/blood-2015-01-623900

Published: 2015

Includes: Supplemental data

Journal Articles

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

Beth Christian, MD, Lai Wei, Jennifer Sexton, Samantha M. Jaglowski, MD MPH, Steven M. Devine, MD, Todd A. Fehniger, MD PhD, Nina Wagner-Johnston, Nancy L. Bartlett, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3099.

https://doi.org/10.1182/blood.V124.21.3099.3099

Published: 2014

Journal Articles

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Manish Patel, Paul Hamlin, MD, Donald K Strickland, MD, Anjali Pandey, PhD, Greg Coffey, PhD, Janet M Leeds, PhD, Gallia G. Levy, MD PhD, John T. Curnutte, MDPhD, Nina Wagner-Johnston, Ian W. Flinn, MD

Blood (2014) 124 (21): 3103.

https://doi.org/10.1182/blood.V124.21.3103.3103

Published: 2014

Journal Articles

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Sonali M. Smith, MD, Brandelyn Pitcher, MS, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, Nina Wagner-Johnston, MD, Steven I. Park, MD, Kristy L. Richards, MDPhD, Amanda F. Cashen, MD, Bruce D. Cheson, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3091.

https://doi.org/10.1182/blood.V124.21.3091.3091

Published: 2014

Journal Articles

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

Myron S. Czuczman, MD, Andrew Davies, BM PhD, Kim M Linton, MBChB, MRCP, PhD, Nina Wagner-Johnston, Randy D. Gascoyne, MD, David A. Eberhard, MD PhD, Gilles Salles, MDPhD, Thomas E. Witzig, MD, Pier Luigi Zinzani, MD, PhD, George W. Wright, PhD, Louis M. Staudt, MD PhD, Jacqueline Repici, Dale Song, Oliver Manzke, MD, Ian D Lewis, MBBS, PhD

Blood (2014) 124 (21): 628.

https://doi.org/10.1182/blood.V124.21.628.628

Published: 2014

Journal Articles

High Frequency of Identical Lymphoma Clones Detected in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas: Prospective Multicenter Trial of the AIDS Malignancy Consortium (AMC 064)

Nina Wagner-Johnston, Jeannette Y. Lee, Sylvia Silver, Ariela Noy, Martha P. Mims, Francois Pepin, Martin Moorhead, PhD, Malek Faham, Richard F. Ambinder

Blood (2014) 124 (21): 1680.

https://doi.org/10.1182/blood.V124.21.1680.1680

Published: 2014

NARROW

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Postibrutinib outcomes in patients with mantle cell lymphoma

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

High Frequency of Identical Lymphoma Clones Detected in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas: Prospective Multicenter Trial of the AIDS Malignancy Consortium (AMC 064)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only